198 related articles for article (PubMed ID: 27611765)
1. Structural basis for the Zn2+ inhibition of the zymogen-like kallikrein-related peptidase 10.
Debela M; Magdolen V; Bode W; Brandstetter H; Goettig P
Biol Chem; 2016 Dec; 397(12):1251-1264. PubMed ID: 27611765
[TBL] [Abstract][Full Text] [Related]
2. Structural basis of the zinc inhibition of human tissue kallikrein 5.
Debela M; Goettig P; Magdolen V; Huber R; Schechter NM; Bode W
J Mol Biol; 2007 Nov; 373(4):1017-31. PubMed ID: 17881000
[TBL] [Abstract][Full Text] [Related]
3. Coagulation factor XII protease domain crystal structure.
Pathak M; Wilmann P; Awford J; Li C; Hamad BK; Fischer PM; Dreveny I; Dekker LV; Emsley J
J Thromb Haemost; 2015 Apr; 13(4):580-91. PubMed ID: 25604127
[TBL] [Abstract][Full Text] [Related]
4. Kallikrein-related peptidase-8 (KLK8) is an active serine protease in human epidermis and sweat and is involved in a skin barrier proteolytic cascade.
Eissa A; Amodeo V; Smith CR; Diamandis EP
J Biol Chem; 2011 Jan; 286(1):687-706. PubMed ID: 20940292
[TBL] [Abstract][Full Text] [Related]
5. A structural model for the prostate disease marker, human prostate-specific antigen.
Villoutreix BO; Getzoff ED; Griffin JH
Protein Sci; 1994 Nov; 3(11):2033-44. PubMed ID: 7535613
[TBL] [Abstract][Full Text] [Related]
6. Enzymatic action of human glandular kallikrein 2 (hK2). Substrate specificity and regulation by Zn2+ and extracellular protease inhibitors.
Lövgren J; Airas K; Lilja H
Eur J Biochem; 1999 Jun; 262(3):781-9. PubMed ID: 10411640
[TBL] [Abstract][Full Text] [Related]
7. Crystal structure of the proenzyme domain of plasminogen.
Peisach E; Wang J; de los Santos T; Reich E; Ringe D
Biochemistry; 1999 Aug; 38(34):11180-8. PubMed ID: 10460175
[TBL] [Abstract][Full Text] [Related]
8. Chymotryptic specificity determinants in the 1.0 A structure of the zinc-inhibited human tissue kallikrein 7.
Debela M; Hess P; Magdolen V; Schechter NM; Steiner T; Huber R; Bode W; Goettig P
Proc Natl Acad Sci U S A; 2007 Oct; 104(41):16086-91. PubMed ID: 17909180
[TBL] [Abstract][Full Text] [Related]
9. Crystal structure of recombinant human tissue kallikrein at 2.0 A resolution.
Katz BA; Liu B; Barnes M; Springman EB
Protein Sci; 1998 Apr; 7(4):875-85. PubMed ID: 9568894
[TBL] [Abstract][Full Text] [Related]
10. Structure-function analyses of human kallikrein-related peptidase 2 establish the 99-loop as master regulator of activity.
Skala W; Utzschneider DT; Magdolen V; Debela M; Guo S; Craik CS; Brandstetter H; Goettig P
J Biol Chem; 2014 Dec; 289(49):34267-83. PubMed ID: 25326387
[TBL] [Abstract][Full Text] [Related]
11. Structure of plasma and tissue kallikreins.
Pathak M; Wong SS; Dreveny I; Emsley J
Thromb Haemost; 2013 Sep; 110(3):423-33. PubMed ID: 23494059
[TBL] [Abstract][Full Text] [Related]
12. Crystal structure of a prostate kallikrein isolated from stallion seminal plasma: a homologue of human PSA.
Carvalho AL; Sanz L; Barettino D; Romero A; Calvete JJ; Romão MJ
J Mol Biol; 2002 Sep; 322(2):325-37. PubMed ID: 12217694
[TBL] [Abstract][Full Text] [Related]
13. Structural Studies on the Inhibitory Binding Mode of Aromatic Coumarinic Esters to Human Kallikrein-Related Peptidase 7.
Hanke S; Tindall CA; Pippel J; Ulbricht D; Pirotte B; Reboud-Ravaux M; Heiker JT; Sträter N
J Med Chem; 2020 Jun; 63(11):5723-5733. PubMed ID: 32374603
[TBL] [Abstract][Full Text] [Related]
14. Biochemical and functional characterization of the human tissue kallikrein 9.
Filippou PS; Farkona S; Brinc D; Yu Y; Prassas I; Diamandis EP
Biochem J; 2017 Jul; 474(14):2417-2433. PubMed ID: 28559305
[TBL] [Abstract][Full Text] [Related]
15. Three dimensional structures of S189D chymotrypsin and D189S trypsin mutants: the effect of polarity at site 189 on a protease-specific stabilization of the substrate-binding site.
Szabó E; Venekei I; Böcskei Z; Náray-Szabó G; Gráf L
J Mol Biol; 2003 Aug; 331(5):1121-30. PubMed ID: 12927546
[TBL] [Abstract][Full Text] [Related]
16. Exploring the active site binding specificity of kallikrein-related peptidase 5 (KLK5) guides the design of new peptide substrates and inhibitors.
de Veer SJ; Swedberg JE; Brattsand M; Clements JA; Harris JM
Biol Chem; 2016 Dec; 397(12):1237-1249. PubMed ID: 26894578
[TBL] [Abstract][Full Text] [Related]
17. A potent, proteolysis-resistant inhibitor of kallikrein-related peptidase 6 (KLK6) for cancer therapy, developed by combinatorial engineering.
Sananes A; Cohen I; Shahar A; Hockla A; De Vita E; Miller AK; Radisky ES; Papo N
J Biol Chem; 2018 Aug; 293(33):12663-12680. PubMed ID: 29934309
[TBL] [Abstract][Full Text] [Related]
18. Structure of human pro-chymase: a model for the activating transition of granule-associated proteases.
Reiling KK; Krucinski J; Miercke LJ; Raymond WW; Caughey GH; Stroud RM
Biochemistry; 2003 Mar; 42(9):2616-24. PubMed ID: 12614156
[TBL] [Abstract][Full Text] [Related]
19. Crystal structure of the inhibitor-free form of the serine protease kallikrein-4.
Riley BT; Hoke DE; McGowan S; Buckle AM
Acta Crystallogr F Struct Biol Commun; 2019 Aug; 75(Pt 8):543-546. PubMed ID: 31397325
[TBL] [Abstract][Full Text] [Related]
20. Surface loops of trypsin-like serine proteases as determinants of function.
Goettig P; Brandstetter H; Magdolen V
Biochimie; 2019 Nov; 166():52-76. PubMed ID: 31505212
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
